TP53 Mutations Promote Immunogenic Activity in Breast Cancer

BACKGROUND: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying BC patients responsive to immunotherapy. TP53 mutations were often...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Oncol
Asıl Yazarlar: Liu, Zhixian, Jiang, Zehang, Gao, Yingsheng, Wang, Lirui, Chen, Cai, Wang, Xiaosheng
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Hindawi 2019
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582869/
https://ncbi.nlm.nih.gov/pubmed/31275382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/5952836
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller